PrecisionPath™ Screening and Supportive Care Journey

Below is the structured sequence of interactions, including consent, education, and consultations for the client’s journey. Each step includes a brief description and a scripted narrative.

Step 1: Assessment (Pre-Testing)

Objective: Educate the client on the value of RGCC testing, discuss their concerns, and obtain consent for the Onco-D-Clare test.

Interaction Type: In-person or virtual consultation with the client/patient educator.

Scripted Narrative:

Thank you for considering RGCC testing as part of your proactive health journey. The Onco-D-Clare test detects cancer-specific molecules in your bloodstream, offering early insight into potential cancer activity. This advanced diagnostic tool allows us to detect changes at the cellular level long before traditional methods might.

If the results are positive, we will take additional steps to refine the diagnosis with tests such as OncoTrace and Onconomics Plus, ensuring the most precise understanding of your situation; utilizing the biomarkers and detailed insight offered by the RGCC testing.

We design a highly personalized plan to address the findings.  The plan includes a root-cause approach to restoring wellness, supportive medications, and supplements that are selected, using the specific data providing the genetics and current mechanism the cancer uses to thrive. Lifestyle and diet recommendations are also made based on utilizing these insights.

Before moving forward, we want to ensure you feel fully informed and comfortable.

An overview of the testing process and consent for your review.

ONCO-D-CLARE IS CANCER SCREENING with 93% accuracy

A positive result from the Onco-D-Clare test indicates that the gene expression profile of the peripheral blood mononuclear cells (PBMCs) in the patient's blood sample matches the pattern associated with cancer. Based on the analysis of over 90 genes, the test has detected molecular signatures suggesting cancerous activity, even if no symptoms are currently present.

Key points about a positive result include:

1. Early Detection of Cancer: A positive result suggests that cancer may develop before symptoms appear, allowing for early intervention and treatment options that can significantly improve outcomes.
2. High Accuracy and Reliability: The Onco-D-Clare test is clinically validated and offers a high accuracy rate of approximately 93%, providing confidence in the result's reliability.
3. Informed Decision-Making: This result empowers individuals with essential information about their health, enabling them to make proactive and well-informed decisions about further diagnostic testing, lifestyle changes, or preventive measures.
4. Potential for Personalized Care: Identifying cancer early through gene expression analysis can lead to more tailored monitoring and treatment strategies, improving the overall patient’s health and well-being management.

In summary, a positive result from the Onco-D-Clare test provides critical insights into an individual’s cancer risk, guiding future health decisions and potentially enabling early and more effective interventions.

POSITIVE: The Onco-D-Clare is not definitive. Early Detection of Cancer: A positive result suggests that cancer may develop before symptoms appear, allowing for early intervention and treatment options that can significantly improve outcomes. It doesn't mean that a tumor has yet formed.

The next step is the Oncotrace (run it as a CUP, not a healthy screening). If Onco-D-Clare is positive, you can progress to the aCGH to try and determine the origin or the Onconomics Plus (also run as a CUP or if there were markers that gave origin on the Oncotrace (i.e., PSMA), then use that as the diagnosis) to find out more about cancer and what you can do about it. 

If you run the aCGH test, please understand that it will only be positive when a tumor is present because of chromosomal abnormalities, so you still have around a 20-30% chance that it won't be able to determine the origin either. If that is the case, then you can progress to imaging.

Step 2: Post-Test Education and Results Review (Onco-D-Clare)

Objective: Discuss results and next steps based on the findings.

• Negative Results: Provide reassurance and preventive recommendations.
• Positive Results: Introduce OncoTrace and Onconomics Plus testing.
  Interaction Type: Follow-up consultation.

Scripted Narrative (Negative):
“Great news—your Onco-D-Clare test did not detect circulating tumor cells. While this is reassuring, we recommend ongoing proactive health monitoring to maintain your well-being. Let’s discuss lifestyle strategies and preventive steps tailored to you.”

Scripted Narrative (Positive):
“The Onco-D-Clare test has detected circulating tumor cells (CTCs), which means we can act early. To better understand the nature of these cells and how best to address them, we recommend moving forward with additional testing—OncoTrace and Onconomics Plus. These tests will provide detailed genetic and molecular insights, helping us create a highly targeted plan as an option to consider to address your needs.”

DETECTION OF CIRCULATING CANCER CELLS (CTC)

A positive result from the Oncotrace test indicates that circulating tumor cells (CTCs) and circulating cancer stem cells (CSCs) have been detected in the blood sample, suggesting the presence of cancerous activity. This test can identify CTCs from all cancer types, except those originating from the central nervous system (CNS), and provides valuable information about the current state of the disease, including prognosis and potential aggressiveness.

Key insights from a positive result include:

1. Presence of Cancer Cells: The detection of CTCs confirms the presence of cancer cells in the bloodstream, which may indicate an active cancer process, either from a newly diagnosed condition or residual disease after treatment.
2. Asessment of Tumor Characteristics: The test identifies phenotype markers that can reveal the tissue of origin, offering insights into the specific type of cancer present.
3. Prognostic Information: Oncotrace detects stemness markers that provide critical information on the activity level of CTCs. This helps assess the potential for cancer to proliferate, metastasize, resist treatment, or recur, giving a clearer picture of the cancer’s behavior and aggressiveness.
4. Monitoring Treatment Effectiveness: A positive result can establish a baseline for understanding the effectiveness of ongoing treatment protocols, helping healthcare providers adjust strategies if necessary.
5. Early Detection of Recurrence: For patients in remission, a positive result serves as an early warning system, detecting the potential recurrence of cancer before symptoms develop or other diagnostic tools can identify it.

Overall, a positive Oncotrace result provides essential data that supports personalized care, continuous monitoring, and timely adjustments in treatment to optimize patient outcomes and long-term health management.

Step 3: Post-OncoTrace and Onconomics Plus Results Review

Objective: Present results, discuss findings, and introduce the Supportive Care Plus Cell Therapy Plan.

Interaction Type: Detailed consultation with the functional practitioner and coordinator.

Scripted Narrative:
The results from the OncoTrace and Onconomics Plus tests have provided critical insights into the nature of the circulating tumor cells, including potential treatment strategies. Based on these findings, we recommend a personalized Supportive Care Plus Cell Therapy Plan.

This plan spans 52 weeks and is designed to address your health comprehensively to restore wellness. It includes advanced therapies like Q Restrain infusions, lifestyle interventions, supplements, compounded medications, wellness procedures, and regular monitoring to optimize outcomes.

Step 4: Onboarding for Supportive Care Plus….

Objective: Complete the transaction, obtain consent, set expectations, and educate the client on the plan structure and their expected journey and participation.
Interaction Type: Dedicated onboarding session with the patient advocate.

Scripted Narrative:
The Supportive Care Plus Plan is a 52-week journey tailored to your unique health profile. You’ll have monthly check-ins with your coordinator, lab testing every four months to monitor progress, and consultations with your functional practitioner to review results and adjust the plan as needed.

The plan may include Q Restrain infusions every four months and assessments to determine eligibility for additional cell and immunotherapy strategies. Our team will guide you every step of the way, ensuring you’re supported and well-informed throughout this journey."

WHO IS NOT ELIGIBLE FOR RGCC THERAPY

Radioactive Seeds: Patients are permanently not eligible for therapy due to the prolonged and undetermined time of the radiation exposure

Gamma Delta T Cell Therapy (GDTC): Patients are permanently not eligible for therapy due to the potential interaction with RGCC therapies

Step 5: Orientation to Supportive Care Plus….

Objective: Determine Essential Medications and review the protocol. Discuss goals, expectations, participation, and the client's journey details.
Interaction Type: Dedicated orientation with the program coordinator.

Scripted Narrative:
You’ll have monthly check-ins with your coordinator, lab testing every four months to monitor progress, and consultations with your functional practitioner to review results and adjust the plan as needed.  Cell therapy and immunotherapy are delivered after lab results are reviewed.

Please be sure to “confirm” the SMS messages for understanding.  You will be contacted if you have not “confirmed” after 48 hours. Our team will guide you every step of the way, ensuring you’re supported and well-informed throughout this journey.

Describe all medications that are prescribed for you, including medication name, strength, dose, frequency, prescribing provider, and reason for prescription. This list must be kept up to date throughout the program.

Review the daily supportive medications and supplements.

Review the rotating supportive supplements.

Review the rotating wellness procedure and IV list.

Review the start and stop automation and the need to “confirm.”

Schedule regular weekly or biweekly coaching sessions to ensure support and success.

WHO IS NOT ELIGIBLE FOR RGCC THERAPY

Someone unwilling to make a participation pledge.

Step 6: Ongoing Weekly or Biweekly Coaching Sessions

Objective: Provide lifestyle guidance and support, answer questions, and ensure compliance with the lifestyle plan.
Interaction Type: Weekly or biweekly video conference or phone calls with the Coach.

Scripted Narrative:
"Hi [Client Name], this is your coaching session. Let’s review your progress and address any adjustments or challenges you’re experiencing."

Step 7: Ongoing Monthly Coordinator Visits

Objective: Provide guidance, answer questions, and ensure compliance with the plan.
Interaction Type: Monthly video or phone calls with the coordinator.

Scripted Narrative:
“Hi [Client Name], this is your monthly check-in to discuss how you’re feeling, answer any questions, and ensure you have everything you need to stay on track. Let’s review your progress and address any adjustments or challenges you’re experiencing.”

Step 6: Lab Testing and Practitioner Consultations (Every 4 Months)

Objective: Monitor progress, interpret lab results, and adjust the care plan.
Interaction Type: Lab testing followed by a detailed practitioner consultation.

Scripted Narrative:
"Your lab results provide valuable insights into how your body responds to the care plan. Based on these findings, we’ll make any necessary adjustments to optimize your progress. We aim to ensure every aspect of your plan works for you, so let’s dive into the results and next steps."

Step 7: Evaluation for Additional Cell Therapy (Mid-Journey)

Objective: Determine eligibility for advanced therapies such as dendritic cell therapy or cancer vaccines.
Interaction Type: Practitioner review and consultation.

Scripted Narrative:
"As part of our comprehensive approach, we evaluate opportunities for additional therapies to enhance your care plan further. We may recommend options like dendritic cell therapy or personalized cancer vaccines, depending on your progress and eligibility. These strategies could play a pivotal role in supporting your long-term health."

Step 8: Conclusion of 52-Week Journey and Transition to Maintenance

Objective: Review progress, finalize the journey, and transition to long-term maintenance care.
Interaction Type: Final consultation with the practitioner.

Scripted Narrative:
"Congratulations on completing your 52-week journey! Your commitment has been instrumental in achieving these incredible results. While this phase is complete, maintaining your progress is our priority. Discuss a long-term maintenance plan to ensure continued success and optimal health."

Final Notes:

Each interaction reinforces the client’s confidence in the process and ensures clear communication, emotional support, and actionable guidance. Let me know if you’d like me to refine or expand any step!